Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting

Clinical Cardiology

Volumn 39, Issue 10, 2016, Pages 555-564

  Cannon, Christopher P ^a,b,c   Gropper, Savion ^d   Bhatt, Deepak L ^b,c   Ellis, Stephen G ^e   Kimura, Takeshi ^f   Lip, Gregory Y H ^g   Steg, Ph Gabriel ^h,i   ten Berg, Jurriën M ^j   Manassie, Jenny ^k   Kreuzer, Jörg ^d,l   Blatchford, Jon ^k   Massaro, Joseph M ^m   Brueckmann, Martina ^d,l   Ferreiros Ripoll, Ernesto ^d   Oldgren, Jonas ⁿ   Hohnloser, Stefan H ^o  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e LERNER RESEARCH INSTITUTE   (United States)

^f KYOTO UNIVERSITY   (Japan)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h BICHAT HOSPITAL   (France)

ⁱ ROYAL BROMPTON HOSPITAL   (United Kingdom)

^j ST ANTONIUS HOSPITAL   (Netherlands)

^k BOEHRINGER INGELHEIM LTD   (United Kingdom)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

ⁿ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^o GOETHE UNIVERSITY   (Germany)

more..

Author keywords

Anti platelet therapy; Arrhythmia all; Cardiac; catheterization diagnostic interventional; Clinical trials; General clinical cardiology; management; Pharmacology; Stroke prevention; Thrombosis hypercoagulable states

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DABIGATRAN ETEXILATE; PRASUGREL; TICAGRELOR; WARFARIN; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; DABIGATRAN; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY STENTING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EMBOLISM; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NONVALVULAR ATRIAL FIBRILLATION; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOEMBOLISM; ADVERSE EFFECTS; BLEEDING; CHEMICALLY INDUCED; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DEVICES; METHODOLOGY; MYOCARDIAL INFARCTION; RISK FACTOR; STENT; STROKE; TIME FACTOR; TREATMENT OUTCOME;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; CLINICAL PROTOCOLS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DABIGATRAN; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RESEARCH DESIGN; RISK FACTORS; STENTS; STROKE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84983444661     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22572     Document Type: Article

References (42)

1. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175–179.
2. Ezekowitz MD, Bridgers SL, James KE, et al; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation [published correction appears in N Engl J Med. 1993;328:148]. N Engl J Med. 1992;327:1406–1412.
3. Mant J, Hobbs FD, Fletcher K, et al; BAFTA Investigators, Midland Research Practices Network. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493–503.
4. Connolly S, Pogue J, Hart R, et al.: ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–1912.
5. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527–539.
6. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687–691.
7. Leon MB, Baim DS, Popma JJ, et al; Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665–1671.
8. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084–1089.
9. Nieuwlaat R, Capucci A, Camm AJ, et al; European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422–2434.
10. Nikolsky E, Mehran R, Dangas GD, et al. Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). Am J Cardiol. 2012;109:831–838.
11. Andrade JG, Deyell MW, Khoo C, et al. Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis. Can J Cardiol. 2013;29:204–212.
12. Verheugt FW. Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous? Am Heart J. 2012;163:531–534.
13. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185–1193.
14. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32:1854–1864.
15. Suh JW, Mehran R, Claessen BE, et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2011;58:1750–1756.
16. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010;363:1877]. N Engl J Med. 2009;361:1139–1151.
17. Connolly SJ, Wallentin L, Yusuf S. Additional events in the RE-LY trial. N Engl J Med. 2014;371:1464–1465.
18. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634–640.
19. Dewilde WJ, Oirbans T, Verheugt FW, et al.; WOEST Study Investigators Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–1115.
20. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981–989.
21. Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65:1619–1629.
22. Bhatt DL. When is a double better than a TRIPLE?: stenting in patients with atrial fibrillation. J Am Coll Cardiol. 2015;65:1630–1632.
23. Vardi M, Debidda M, Bhatt DL, et al. Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists. Clin Cardiol. 2014;37:103–107.
24. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol. 2014;64:2305–2307]. J Am Coll Cardiol. 2014;64:e1–e76.
25. Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155–3179.
26. Steg PG, Bhatt DL. Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. Eur Heart J Acute Cardiovasc Care. 2015. pii:2048872615610868.
27. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–2619.
28. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016. pii:CIR.0000000000000404.
29. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–239.
30. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110:1087–1107.
31. Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2060–2066.
32. Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166.
33. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–694.
34. Jackson K, Gersh BJ, Stockbridge N, et al; Duke Clinical Research Institute/American Heart Journal Expert Meeting on Antithrombotic Drug Development for Atrial Fibrillation. Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25–27, 2005. Am Heart J. 2008;155:829–840.
35. Wang TY, Robinson LA, Ou FS, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J. 2008;155:361–368.
36. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–1974.
37. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125:669–676.
38. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–164.
39. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375:283–293.
40. Bhatt DL, Hirsch AT, Ringleb PA, et al; CAPRIE Investigators. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J. 2000;140:67–73.
41. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective. Thromb Haemost. 2011;106:572–584.
42. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28:726–732.